As a treatment for MS, CNP-SMAR1 has three therapeutic values (i) opposition of Th17 differentiation, (ii) increment in the anti-inflammatory IL-10 production by favoring Treg differentiation, and (iii) promotion of the self-tolerance to myelin. Here, CNP is linked to myeloid sarcoma.